IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Bristol Myers Squibb forecasts upbeat 2026 results behind strategic Eliquis price cuts

Bristol Myers expects 2026 revenue to beat estimates as Eliquis price cuts drive growth. Strong Opdivo sales also helped top recent quarterly expectations.

Insights:
Bristol-Myers Squibb Company announced its 2026 financial guidance on February 5, 2026, forecasting total revenue between $46.0 billion and $47.5 billion. The company stated that this range is above Wall Street estimates and includes specific revenue and adjusted earnings per share ranges. This announcement, which is a company-level development, reflects a strategic response to US USUS Medicare price negotiations established under the Inflation Reduction Act.
A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., on May 20, 2021. REUTERS/Brian Snyder
A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., on May 20, 2021. REUTERS/Brian Snyder
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.